# Sofosbuvir/Velpatasvir Fixed-Dose Combination and Ribavirin for 12 or 24 Weeks in Participants With Chronic Genotype 1 or 2 Hepatitis C Virus Infection Who Have Previously Failed a Direct-Acting Antiviral-Containing Regimen

> **NCT02822794** · PHASE3 · COMPLETED · sponsor: **Gilead Sciences** · enrollment: 117 (actual)

## Conditions studied

- Hepatitis C Virus Infection

## Interventions

- **DRUG:** SOF/VEL
- **DRUG:** RBV

## Key facts

- **NCT ID:** NCT02822794
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-07-25
- **Primary completion:** 2017-06-02
- **Final completion:** 2017-08-25
- **Target enrollment:** 117 (ACTUAL)
- **Last updated:** 2018-11-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02822794

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02822794, "Sofosbuvir/Velpatasvir Fixed-Dose Combination and Ribavirin for 12 or 24 Weeks in Participants With Chronic Genotype 1 or 2 Hepatitis C Virus Infection Who Have Previously Failed a Direct-Acting Antiviral-Containing Regimen". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT02822794. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*